GLP-1 drugs and cancer risk: what the 2026 data shows

The headline number on GLP-1 drugs and cancer risk

In 2026, Annals of Oncology published a target trial emulation, a study design built to mimic a randomized trial using real-world data, covering more than 160,000 adults with obesity who did not have diabetes. Patients were followed for a median of two years. People taking a GLP-1 receptor agonist had a 41% lower risk of developing an obesity-associated cancer than those who were not.

The effect was not uniform. Men saw a 68% risk reduction, roughly double the rate seen across both sexes combined. Lead author A.H.-C. Hsu and colleagues were careful about the limits of the finding: if confirmed in prospective trials, GLP-1 drugs may turn out to have a clinical profile that extends well past weight loss and diabetes control. That is a big "if."

A second, larger study points the same direction

The Annals of Oncology finding is not a one-off. Dai and colleagues ran a retrospective cohort study, published in JAMA Oncology, pulling electronic health records from 14 health systems between 2014 and 2024. They matched 43,317 adults with obesity who were prescribed a GLP-1 drug, semaglutide, tirzepatide, or liraglutide, against 43,315 nonusers with comparable health profiles. Cancer incidence came in at 13.6 cases per 1,000 person-years among users versus 16.4 among nonusers, a hazard ratio of 0.83, or a 17% lower relative risk.

Two independent research groups, two different data sources, two different statistical approaches, and both land on a lower cancer rate among GLP-1 users. That kind of replication is what makes this worth writing about rather than filing away as a single surprising headline.

Which cancers move, and which do not

Obesity is a recognized risk factor for 13 cancer types: breast, colorectal, endometrial, kidney, pancreatic, thyroid, ovarian, esophageal, gastric, liver, and gallbladder cancers, plus multiple myeloma and meningioma. Together they account for roughly 40% of all cancers diagnosed in high-income countries. That is the pool researchers are watching.

Endometrial cancer, one of the malignancies most tightly linked to excess body weight, showed the clearest drop, 58% lower in the Annals of Oncology data. The JAMA Oncology cohort separately found reduced rates of endometrial, ovarian, and meningioma cases among GLP-1 users. Not everything pointed the same way. That same cohort flagged a possible increased risk of kidney cancer among users, a single signal that has not been replicated elsewhere and needs more follow-up before anyone reads much into it.

What this means if you already have cancer

A separate question, and a separate body of evidence, concerns people already diagnosed. An ASCO-presented analysis covering more than 10,000 patients with existing solid tumors found GLP-1 use associated with a lower rate of cancer progression, including reduced spread in lung, breast, colon, and liver cancers. That is a meaningfully different claim from cancer prevention in a healthy population, and it is earlier-stage evidence. GLP-1 drugs are not approved to treat cancer, and no oncology group has changed treatment guidance based on it. It is worth tracking, not acting on.

The thyroid cancer question, addressed directly

Anyone who has read the label on Ozempic, Wegovy, or Zepbound has seen the boxed warning about thyroid C-cell tumors. That warning exists because semaglutide and tirzepatide both caused dose-dependent thyroid C-cell tumors, including medullary thyroid carcinoma, in long-term rodent studies. It is why both drugs are contraindicated in anyone with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2.

That rodent finding and the cancer-risk-reduction data above are not in tension, because they are not describing the same thing. Systematic reviews of the available human data have not found conclusive evidence that GLP-1 drugs increase thyroid cancer risk in people. The label warning reflects an animal safety signal FDA requires companies to disclose. The 2026 cohort studies reflect real-world human cancer incidence across a different set of cancer types entirely. Both can be true at once.

Is this just about weight loss, or something else?

Researchers do not yet know how much of this effect is simply the weight loss itself. Losing body fat reduces circulating estrogen, lowers chronic inflammation, and improves insulin sensitivity, all mechanisms independently linked to lower cancer risk. That is the weight-dependent pathway, and it would apply to any effective weight-loss intervention, not just GLP-1 drugs specifically.

There is also a weight-independent hypothesis. GLP-1 receptors sit on immune cells and in tissues beyond the gut and brain, and some researchers think the drugs may directly dampen the chronic low-grade inflammation and insulin/IGF-1 signaling that helps some tumors grow, separate from any pounds lost. Nobody has isolated the two effects in humans yet. Until a trial does, treat "how" as an open question even where "how much" looks fairly consistent across studies.

The limits of what these studies can prove

Both major studies are observational, not randomized controlled trials. People prescribed a GLP-1 drug are not a random sample of everyone with obesity. They tend to be engaged with their healthcare, have better access to screening, and may differ from nonusers in ways that are hard to fully match for statistically, a problem researchers call residual confounding. Reverse causation is a related concern in cancer research generally: people with undiagnosed early cancer sometimes lose weight before diagnosis, which can distort the direction of an association if not carefully controlled for. Both research teams used matching and modeling designed to reduce these problems, but they cannot eliminate them the way a randomized trial would.

Median follow-up in the Annals of Oncology study was two years. Most cancers take far longer than that to develop, so this is early data on a slow-moving outcome. Prospective, randomized trials designed specifically to test cancer incidence as an endpoint would settle the question. None have reported results yet.

The bottom line on GLP-1 drugs and cancer risk

The signal is real, consistent across two independent large studies, and biologically plausible given what is already known about obesity and cancer. It is not proof, and it is not a reason to start a GLP-1 drug if you would not otherwise be a candidate for one. For people already being treated for type 2 diabetes or obesity, this is a genuinely encouraging secondary finding layered on top of the drugs' established benefits, which also include reduced cardiovascular risk and, in earlier research, lower rates of alcohol use disorder. It joins a growing list of effects researchers are still mapping well beyond the original diabetes and weight-loss indications, alongside ongoing work on brain health and metabolic disease. For now, cancer risk reduction belongs in that same category: a real, watched, unproven-but-promising research thread, not a reason on its own to start treatment.